The stock price of BridgeBio Pharma Inc (NASDAQ: BBIO) has dropped by -3.94 compared to previous close of 29.98. Despite this, the company has seen a fall of -2.01% in its stock price over the last five trading days. Reuters reported 2024-03-04 that BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday.
Is It Worth Investing in BridgeBio Pharma Inc (NASDAQ: BBIO) Right Now?
Moreover, the 36-month beta value for BBIO is 1.03. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BBIO is 136.57M and currently, short sellers hold a 9.82% of that float. On April 03, 2024, BBIO’s average trading volume was 1.81M shares.
BBIO’s Market Performance
BBIO stock saw a decrease of -2.01% in the past week, with a monthly decline of -19.17% and a quarterly a decrease of -28.66%. The volatility ratio for the week is 4.44%, and the volatility levels for the last 30 days are 4.98% for BridgeBio Pharma Inc (BBIO).. The simple moving average for the past 20 days is -1.61% for BBIO’s stock, with a -3.69% simple moving average for the past 200 days.
Analysts’ Opinion of BBIO
Many brokerage firms have already submitted their reports for BBIO stocks, with Raymond James repeating the rating for BBIO by listing it as a “Outperform.” The predicted price for BBIO in the upcoming period, according to Raymond James is $45 based on the research report published on March 21, 2024 of the current year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $37. The rating they have provided for BBIO stocks is “Market Perform” according to the report published on January 31st, 2024.
Wells Fargo gave a rating of “Overweight” to BBIO, setting the target price at $58 in the report published on December 08th of the previous year.
BBIO Trading at -12.37% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.02% of loss for the given period.
Volatility was left at 4.98%, however, over the last 30 days, the volatility rate increased by 4.44%, as shares sank -10.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.40% lower at present.
During the last 5 trading sessions, BBIO fell by -2.01%, which changed the moving average for the period of 200-days by +70.52% in comparison to the 20-day moving average, which settled at $29.09. In addition, BridgeBio Pharma Inc saw -28.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from Scott Randal W., who sale 2,500 shares at the price of $34.00 back on Mar 01 ’24. After this action, Scott Randal W. now owns 6,500 shares of BridgeBio Pharma Inc, valued at $85,000 using the latest closing price.
Valantine Hannah, the Director of BridgeBio Pharma Inc, sale 2,915 shares at $37.75 during a trade that took place back on Feb 15 ’24, which means that Valantine Hannah is holding 1,764 shares at $110,041 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -65.29 for the present operating margin
- 0.74 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -73.08. The total capital return value is set at -1.51.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated 4.51 points at debt to capital in total, while cash flow to debt ratio is standing at -0.3. The debt to equity ratio resting at -1.28. The interest coverage ratio of the stock is -14.93.
Currently, EBITDA for the company is -574.64 million with net debt to EBITDA at -2.35. When we switch over and look at the enterprise to sales, we see a ratio of 717.63. The receivables turnover for the company is 5.31for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.32.
Conclusion
To wrap up, the performance of BridgeBio Pharma Inc (BBIO) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
